Angiotensin-converting enzyme inhibitors

Angiotensin-converting enzyme inhibitors has been studied in 197 papers since 2004: 7 trials and 128 observational studies in people, 1 in animals, 58 reviews; 81 in the past year. The newest paper, Nov 19, 2026: “Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review”.

Intervention

197 papers study it74 findingsUpdated

MeSH

28 new papers in 30 daysSee all 197 papers on angiotensin-converting enzyme inhibitors

At a glance

Independent labs found the same change in people. 43 independent labs in 21 countries.

“The ACEi group reduced the upper body strength, upper and lower body flexibility and aerobic endurance (p<0.05)”
Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medicationExperimental gerontology2017doi:10.1016/j.exger.2017.06.013

8 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 43 independent labs in 21 countries
  • 8 findings against
  • Funders: National Institutes of Health and others
  • 8 of 62 findings with company ties
  • Human trial7
  • Humans128
  • Animals1
  • In silico2

Studies in people

3 studies gave angiotensin-converting enzyme inhibitors to people and measured what changed.

What changedDesignPeopleSource

down: Decreases systolic blood pressuremean decrease of 16.4+/- 3.2 mmHg

up: Increases eGFRmean increase of 5.6+/- 1.8 mL/min/1.73 m 2

Randomized trial12 weeks120 peopleStage 1 hypertensionJournal of pharmacy & bioallied sciences, Dec 17, 2025

no change: Has no effect on mortality

no change: Has no effect on cardiovascular disease

Treated cohortin-trial [4.1-year]+post-trial [6.9-year]648 peopleolderOlder adults; in older patients with lipid-lowering therapy free of CVDHeart & lung : the journal of critical care, Oct 29, 2021

down: Impairs physical functionp<0.05

up: Increases systolic blood pressurep<0.001

Trial2 years418 peopleolder adultsOlder adults; hypertension with comorbiditiesExperimental gerontology, Jun 21, 2017

What did studies of angiotensin-converting enzyme inhibitors find?

34

Studies of angiotensin-converting enzyme inhibitors measured 34 outcomes; the most studied are cognitive decline (3 studies), handgrip strength (2) and age-related macular degeneration (2).

Cognitive decline

downin humans2downin reviews1

3 studies
  1. Angiotensin-converting enzyme inhibitors are linked with lower cognitive decline in humans.

    “Angiotensin-converting enzyme inhibitors and metformin were associated with a slower cognitive decline.”

    Humans

    Cardiometabolic medication exposures and cognitive outcomes in Alzheimer's disease

    Age and ageing

  2. Angiotensin-converting enzyme inhibitors are linked with lower cognitive decline in humans among participants without HTN, compared to non-RAS use.

    “Among participants without HTN, ACEI use was associated with significantly reduced cognitive decline compared to non-RAS use.”

    Humansamong participants without HTN, compared to non-RAS use9 years

    A comparison of drugs targeting the renin-angiotensin system and global cognition in aging

    Journal of Alzheimer's disease : JAD

  3. Angiotensin-converting enzyme inhibitors protect against cognitive decline (reported as potential benefit in some research; other studies inconsistent).

    “While some research highlights the potential benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, other studies show inconsistent results”

    Reviewreported as potential benefit in some research; other studies inconsistent

    Association of Hypertension with Different Cognitive Disorders

    Journal of clinical medicine

Handgrip strength

upin humans1downin humans1

2 studies
  1. Angiotensin-converting enzyme inhibitors are linked with better handgrip strength in humans (congestive heart failure) (P < .001).

    “patients on ACEi demonstrated significantly better HGS and GS compared to non-ACEi patients (P < .001).”

    Humanscongestive heart failure

    Angiotensin-converting enzyme inhibitors attenuate circulating CAF22 and physical decline in congestive heart failure: Diagnostic implications of CAF22

    British journal of clinical pharmacology

  2. Angiotensin-converting enzyme inhibitors are linked with lower handgrip strength in humans (linear regression models).

    “Statins, ACE-inhibitors, ARBs, diuretics, calcium channel blockers, and sulfonylureas showed a consistent and significant decrease in grip strength in linear regression models.”

    Humanslinear regression models

    Association Between Reduced Handgrip Strength and Commonly Prescribed Medications

    medRxivPreprint

Age-related macular degeneration

no changein humans2HR 1.07

2 studies
  1. Angiotensin-converting enzyme inhibitors were not clearly linked with age-related macular degeneration in humans (hypertension) (adjusted HR 1.07 (95% CI 0.90-1.27) weighted; 0.87 (95% CI 0.71-1.07) matched).

    “There was no association of ACE-I use on the risk of AMD compared to CCB use in either the propensity score weighted or matched, on-treatment analysis”

    Humanshypertensionmedian follow-up of 2 yearsn = 53,832

    Angiotensin-converting enzyme inhibitors and risk of age-related macular degeneration in individuals with hypertension

    British journal of clinical pharmacology

  2. Angiotensin-converting enzyme inhibitors were not clearly linked with age-related macular degeneration in humans (OR 0.90 (95% CI 0.61-1.34)).

    “The ORs (95% CI) for AMD occurrence in users prescribed with statins, metformin, ACE inhibitors, and ARBs were 1.12 (0.94-1.32), 1.15 (0.91-1.45), 0.90 (0.61-1.34), and 1.21 (1.05-1.39), respectively.”

    Humansin cohorts with diabetes mellitus or cardiovascular disease; exposure within one year before index daten = 2,330

    Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration

    Yonsei medical journal

More on Age-related macular degeneration

Mortality

no changein humans1downin humans1

2 studies
  1. Angiotensin-converting enzyme inhibitors were not clearly linked with mortality in older patients with lipid-lowering therapy free of CVD.

    “There were no significant differences between the two groups for the primary endpoints over the in-trial plus post-trial follow-up”

    Humansin older patients with lipid-lowering therapy free of CVDin-trial [4.1-year]+post-trial [6.9-year]n = 648

    Antihypertensive drug class in combination with lipid lowering treatment for primary prevention of cardiovascular disease in the elderly

    Heart & lung : the journal of critical care

  2. Angiotensin-converting enzyme inhibitors decrease mortality in humans (heart failure).

    “drugs such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers has meant a great step forward in the treatment of patients with this condition that significantly has decreased mortality and morbidity.”

    Reviewheart failure

    Physical training in chronic heart failure: pathophysiology and clinical evolution

    Medwave

Dementia

no changein humans1

1 study
  1. Angiotensin-converting enzyme inhibitors were not clearly linked with dementia in humans (compared with angiotensin II receptor blockers).

    “There was no significant difference in dementia risk between initiators of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).”

    Humanscompared with angiotensin II receptor blockers

    RAS inhibitors linked to lower dementia risk than CCBs

    Drugs & aging

More on Dementia

CD31+ CXCR4+ Th and Treg cell preservation

upin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors are linked with higher CD31+ CXCR4+ Th and Treg cell preservation in humans (Arterial hypertension).

    “Therapy with ACEI prevented also loss of CD31 + CXCR4+ Th and CD31 + CXCR4+ Treg cells”

    HumansArterial hypertension

    Decreased potential for lymphatic vessel generation is a hallmark of early diagnosed arterial hypertension and can be reversed by treatment with angiotensin converting enzyme inhibitors

    Scientific reports

Serum lymphangiogenic potential

upin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors are linked with higher serum lymphangiogenic potential in humans (Recently diagnosed arterial hypertension; serum activity evaluated in an animal model).

    “Two years after treatment implementation, the lymphangiogenic potential of the patients' sera was restored only in patients treated with angiotensin converting enzyme inhibitors (ACEI).”

    HumansRecently diagnosed arterial hypertension; serum activity evaluated in an animal model2 years

    Decreased potential for lymphatic vessel generation is a hallmark of early diagnosed arterial hypertension and can be reversed by treatment with angiotensin converting enzyme inhibitors

    Scientific reports

Chronic kidney disease

downin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors protect against chronic kidney disease in patients with stage 3 to 5 chronic kidney disease.

    “in patients with stage 3 to 5 chronic kidney disease, limited evidence suggests that ACEIs may confer superior renoprotective benefits.”

    Reviewin patients with stage 3 to 5 chronic kidney disease

    All in on ARBs: Is it time to fold the ACEIs?

    Canadian family physician Medecin de famille canadien

More on Chronic kidney disease

Albuminuria

downin reviews1

1 study
  1. Angiotensin-converting enzyme inhibitors decrease albuminuria (diabetic kidney disease).

    “angiotensin convertase enzyme inhibitors and angiotensin receptor blockers alongside nonpharmacological measures have been the pillars of DKD treatment and reduction of albuminuria for many decades”

    Reviewdiabetic kidney diseasekidney

    Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives

    Kidney & blood pressure research

More on Albuminuria

eGFR

upin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors increase eGFR in humans (Stage 1 hypertension) (mean increase of 5.6+/- 1.8 mL/min/1.73 m 2).

    “the eGFR increased by the largest percentage in group A (ACE inhibitors; mean increase of 5.6+/- 1.8 mL/min/1.73 m 2).”

    Human trialStage 1 hypertension12 weeks

    Comparative Study on the Efficacy of Different Antihypertensive Classes in Early-Stage Hypertension with Renal Function Consideration

    Journal of pharmacy & bioallied sciences

More on eGFR

Systolic blood pressure

downin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors decrease systolic blood pressure in humans (Stage 1 hypertension) (mean decrease of 16.4+/- 3.2 mmHg).

    “The SBP was reduced by the largest percentage in group A (ACE inhibitors; mean decrease of 16.4+/- 3.2 mmHg)”

    Human trialStage 1 hypertension12 weeks

    Comparative Study on the Efficacy of Different Antihypertensive Classes in Early-Stage Hypertension with Renal Function Consideration

    Journal of pharmacy & bioallied sciences

Systolic blood pressure

upin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors increase systolic blood pressure in humans (hypertension with comorbidities) (p<0.001).

    “worsened the anthropometric profile, and SBP (p<0.001)”

    Human trialhypertension with comorbidities2 years

    Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medication

    Experimental gerontology

More on Systolic blood pressure

Physical function

downin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors impair physical function in humans (hypertension with comorbidities) (p<0.05).

    “The ACEi group reduced the upper body strength, upper and lower body flexibility and aerobic endurance (p<0.05)”

    Human trialhypertension with comorbidities2 years

    Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medication

    Experimental gerontology

All 34

What is angiotensin-converting enzyme inhibitors linked with?

28

Studies link angiotensin-converting enzyme inhibitors with 28 measures, most often mortality (4 studies), dementia (3) and Alzheimer's disease (2).

Mortality

downin humans4HR 0.59–0.94

4 studies
  1. Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (compared with CCBs in participants with MASLD receiving monotherapy) (aHR 0.30, 95% CI 0.11-0.82).

    “ACEIs and ARBs were associated with lower all-cause mortality compared with calcium channel blockers (CCBs, reference group; n = 47; 15 deaths) (ACEIs: adjusted hazard ratio [aHR], 0.30; 95% CI, 0.11-0.82”

    Humanscompared with CCBs in participants with MASLD receiving monotherapyn = 458

    Associations of antihypertensive medication class with liver fibrosis and mortality in US adults with MASLD

    Clinical and experimental hypertension (New York, N.Y. : 1993)

  2. Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (target dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohort) (6% lower risk; HR 0.94, 95% CI 0.92-0.97).

    “a 6% lower risk of death (HR, 0.94; 95% CI, 0.92-0.97)”

    Humanstarget dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohorttarget dose5-yearn = 70,860

    Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF

    European journal of heart failure

  3. Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (supratentorial primary malignant brain tumors) (HR 0.59, 95% CI 0.48-0.72).

    “HR:0.71. 95% CI:0.59-0.86; HR:0.59, 95% CI:0.48-0.72; and HR:0.45, 95% CI:0.35-0.58 respectively”

    Humanssupratentorial primary malignant brain tumorsn = 1,943

    Factors associated with longer survival among older medicare patients after diagnosis of supratentorial primary brain malignancies: a retrospective cohort study

    Neurological research

  4. Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (proactive treatment).

    “Proactive treatment with ACE-I/ARBs appeared to significantly reduce future mortality risk”

    Humansproactive treatment

    The principal component-based clinical aging clock (PCAge) identifies signatures of healthy aging and provides normative targets for clinical intervention

    medRxivPreprint

Dementia

downin humans2upin humans1

3 studies
  1. Angiotensin-converting enzyme inhibitors are linked with a higher risk of dementia in humans (baseline hypertension).

    “whereas angiotensin-converting enzyme inhibitors (ACEIs) and diuretics increased risk.”

    Humansbaseline hypertension

    Antihypertensive medications and dementia in older adults with hypertension

    medRxiv : the preprint server for health sciencesPreprint

  2. Angiotensin-converting enzyme inhibitors are linked with a lower risk of dementia in people living with HIV.

    “The results reveal a statistically significant reduction in dementia diagnosis for PLWH exposed to BBB-penetrant ACEi.”

    Humansin people living with HIV

    Exposure to angiotensin-converting enzyme inhibitors that cross the blood-brain barrier and the risk of dementia among patients with human immunodeficiency virus

    medRxiv : the preprint server for health sciencesPreprint

  3. Angiotensin-converting enzyme inhibitors lower the risk of dementia in humans (older adults).

    “In addition, some results found that ACEi and ARB users present delayed cognitive decline and reduced risk of dementia.”

    Reviewolder adults

    Mini-review: Angiotensin- converting enzyme 1 (ACE1) and the impact for diseases such as Alzheimer's disease, sarcopenia, cancer, and COVID-19

    Frontiers in aging

More on Dementia

Alzheimer's disease

upin humans1downin humans1HR 1.23

2 studies
  1. Angiotensin-converting enzyme inhibitors are associated with Alzheimer's disease in humans (Regular users compared with angiotensin receptor blocker users in UK Biobank) (HR 1.23, 95% CI 1.00–1.50).

    “a higher incidence (hazard ratio, 1.23 [95% CI, 1.00-1.50]) of AD among regular users of angiotensin-converting enzyme inhibitors”

    HumansRegular users compared with angiotensin receptor blocker users in UK Biobank

    Genetic analysis links a blood enzyme to Alzheimer’s risk

    Journal of the American Heart Association

  2. Angiotensin-converting enzyme inhibitors are linked with a lower risk of Alzheimer's disease in humans (monotherapy vs calcium channel blockers in older adults with hypertension) (OR 0.36, 95 % CI 0.13-0.99).

    “those who used angiotensin-converting enzyme inhibitors (ACEIs) had significantly lower odds of developing AD compared to those who used CCBs (OR 0.36, 95 % CI 0.13-0.99).”

    Humansmonotherapy vs calcium channel blockers in older adults with hypertensionn = 539

    Antihypertensive Use and the Risk of Alzheimer's Disease and Related Dementias among Older Adults in the USA

    Drugs & aging

More on Alzheimer's disease

COVID-19

downin humans2HR 0.78

2 studies
  1. Angiotensin-converting enzyme inhibitors are linked with a lower risk of COVID-19 in humans (multivariable-adjusted) (HR: 0.78; 95% CI: 0.61-1.00).

    “taking angiotensin-converting-enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00), angiotensin-receptor-blockers (HR: 0.70; 95%CI: 0.51-0.96) and statins (HR: 0.75; 95% CI: 0.58-0.96) were associated with reduced risk.”

    Humansmultivariable-adjustedn = 79,083

    Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain

    Medicina clinica (English ed.)

  2. Angiotensin-converting enzyme inhibitors are linked with a lower risk of COVID-19 in humans (current use compared with never use; diagnosis outcome).

    “current users of ACEI, ARB, statins, warfarin, direct factor Xa inhibitors and P2Y12 inhibitors were associated with reduced risks, compared to never users”

    Humanscurrent use compared with never use; diagnosis outcome

    Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients

    PloS one

More on COVID-19

Range of motion

downin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors are associated with range of motion in humans after arthroscopic rotator cuff repair.

    “ACEI use correlated with worse ROM and patient-reported outcomes, while statins again showed no effect.”

    Reviewafter arthroscopic rotator cuff repairshoulder

    The Role of Systemic Antifibrotic Agents on Patient and Surgical Outcomes After Joint Surgery: A Systematic Review

    The Journal of the American Academy of Orthopaedic Surgeons

Cognitive impairment

upin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors are associated with cognitive impairment in humans (receiving antihypertensive therapy).

    “Conversely, selective beta-blockers and angiotensin-converting enzyme (ACE) inhibitors were associated with an increased probability of impairment.”

    Humansreceiving antihypertensive therapyn = 28,057

    Impact of ARBs plus beta-blockers and other antihypertensives on cognitive impairment: a longitudinal study

    Frontiers in pharmacology

More on Cognitive impairment

Vascular dementia

upin silico1OR 1.12

1 study
  1. Angiotensin-converting enzyme inhibitors raise the risk of vascular dementia in silico (Mendelian randomization) (OR 1.12, 95% CI 1.01-1.24).

    “Angiotensin-converting enzyme inhibition suggested increased VaD risk (OR = 1.12, 95% CI = 1.01-1.24).”

    In silicoMendelian randomization

    Repurposing drugs for the prevention of vascular dementia using evidence from drug target Mendelian randomization

    Nature aging

More on Vascular dementia

Myocardial infarction

downin humans1RR 0.65

1 study
  1. Angiotensin-converting enzyme inhibitors lower the risk of myocardial infarction in humans (compared with placebo) (RR 0.65; 95% CI 0.51-0.82).

    “ACEIs were more effective in reducing myocardial infarction (RR 0.65; 95% CI 0.51-0.82)”

    Reviewcompared with placebo

    Efficacy of Renin Angiotensin Aldosterone System Inhibitors on Cardiovascular Outcomes in Hypertensive Population: A Network Meta-analysis of Randomized Controlled Trials

    Drugs

More on Myocardial infarction

Kidney failure

downin humans1HR 0.82

1 study
  1. Angiotensin-converting enzyme inhibitors are linked with a lower risk of kidney failure in humans (target dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohort) (18% lower risk; HR 0.82, 95% CI 0.75-0.89).

    “In the ACEI cohort, target-dose was associated with a 18% lower risk of KF (HR, 0.82; 95% CI, 0.75-0.89)”

    Humanstarget dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohorttarget dose5-yearn = 70,860

    Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF

    European journal of heart failure

More on Kidney failure

Cardiovascular death, myocardial infarction, stroke, and renal failure

downin humans1RR 0.87

1 study
  1. Angiotensin-converting enzyme inhibitors lower the risk of cardiovascular death, myocardial infarction, stroke, and renal failure in humans (compared to control in type 2 diabetes mellitus) (RR = 0.87, 95% CI = 0.81-0.94).

    “In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control.”

    Reviewcompared to control in type 2 diabetes mellitus

    Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Cureus

All 28

Funding

1 grant since 2020

National Institute on Aging$772K

Latest

Dec 2025: 4Jan 2026: 6Feb 2026: 7Mar 2026: 12Apr 2026: 3May 2026: 2Jun 2026: 3Jul 2026: 4Aug 2026: 2Sep 2026: 5Oct 2026: 25Nov 2026: 679 papers in 12 months

See all 197 papers on angiotensin-converting enzyme inhibitors